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Abstract:
Over the last few decades, understanding of the mecha-
nism of cellular development has increased tremen-
dously. The knowledge of the potential of stem/pre-
cursor cells in tissue engineering and cell therapy has
gained the popularity. In case of diabetes, the availabil-
ity of the source of stem cells and the efficacy of their
isolation techniques for maximum yield of viable cells
to expand is an important issue which needs attention.
Attempts to make beta cells from mouse embryonic
stem cells (ES) and adult stem cells have been frus-
trating in part because too much has been expected
too soon. The problem with ES cells are that it is not
known whether these cells are truly similar to normal
beta cells or not and ethical issues surrounding them.
ES cells is a major concern. Current claims about dif-
ferentiation / transdifferentiation of adult stem cells to
insulin producing cells has been demonstrated by many
groups. These adult stem cells are of enormous inter-
est because of their general accessibility and lack of
ethical issues. Also, adult stem cells are non immuno-
compatible unless isolated from the same patient
whereas ethical and scientific issues surrounding em-
bryonic and fetal stem cells hinder their widespread
implementation. Therefore, much attention is now fo-
cused on alternative sources of adult/postnatal stem
cells.
Keywords: Diabetes, Regenerative medicine, Stem
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Introduction:
Diabetes mellitus (DM) is now taking its place as one
of the main threats to human health in the 21st century
[1, 2]. Over the last century, human lifestyle and
behaviour changes have resulted in a dramatic increase
in the incidence of diabetes worldwide. The past two
decades have seen an explosive (almost 46%) in-
crease in the number of people diagnosed with dia-
betes worldwide, [3-6] with more than 40% from
India only [7]. The global prevalence of diabetes is
shifting significantly from the developed countries to
the developing countries [2].
DM is currently a chronic disease without a cure;
however, type 2 diabetes can be managed with a
combination of dietary treatment, medication, exer-
cise, and insulin supplementation. In case of Type 1
DM, a sustained C-peptide production and success-
ful insulin independence continuously for five years
after pancreatic islet transplantation  has showed a
ray of hope [7]. Since then, the islet transplantation is
increasingly being used as a cell replacement therapy
for type-1 diabetes [8]. However, the need for on-
going immunosuppressive therapy and the scarcity of
donor islets have precluded the widespread adop-
tion of islet transplantation. Although
xenotransplantation (for example, porcine islets) could
provide a virtually inexhaustible source of islets for
transplantation [9, 10] the concern about infection by
animal retroviruses and certain ethical issues limit the
use of this potential source. Hence, there is a need to
look for new sources of islet tissues to meet the po-
tential demand for islet cell transplantation.
Stem cell Therapy as a source for islet neogenesis
A stem cell is defined by their ability to self-renew
indefinitely by asymmetric cell division with a poten-
tial to differentiate into one or more specialized cell-
types [11-13]. Stem cells of embryonic or adult ori-
gin have become the favourable and attractive target
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of research in the biomedical sciences as they offer
solutions to overcome the technical difficulties asso-
ciated with conventional cell therapy by their ability
to proliferate, replicate in a controlled laboratory con-
ditions and to differentiate into a wide range of tissue
types.
In developing a potential therapy for patients with
diabetes, the stem cell system needs to meet several
criteria. For diabetes therapy, it is not clear whether
it will be desirable to produce only â-cells or whether
other types of pancreatic islet cells (PP, α, δ cells)
and acinar cells are also essential.  Recent trends in-
dicate that isolated β cells cultured in the absence of
the other islet cells (α,δ, PP) are less responsive to
changes in glucose concentration than intact islet clus-
ters made up of all islet cell types. Perhaps the most
important issue is the choice of the appropriate
sources of stem cells.
Embryonic Stem Cells:
October 2013, marks the 15th anniversary of the first
reported derivation of human Embryonic Stem (ES)
cells [14]. The report was met with much acclaim as
it was quickly recognized that the ability of these pluri-
potent stem cells derived from the inner mass of the
mammalian blastocyst to differentiate indefinitely into
all cell types/germ layers of the human body; could
provide a source of cells both in vivo and in vitro
for replacing tissues lost to injury and disease - the
ultimate goal of regenerative medicine.
Regardless of the species, undifferentiated ES cells
express several cell surface markers; these include
stage specific embryonic antigen (SSEA), SSEA1 in
mouse and SSEA-3 and SSEA-4 in human, as well
as tumor recognition antigens TRA-1-60 and TRA-
1-81 in human [15-17]. In the uncommitted state both
mouse and human ES cells express alkaline phos-
phatase, the POU-domain transcription factor Oct-
4, and telomerase16. When removed from the spe-
cific culture conditions required to maintain an undif-
ferentiated state, ES cell lines from both species can
spontaneously be  differentiated in vitro to form a
variety of cell types derived from each of the three
germ layers. Even without the addition of any exog-
enous growth factors, ES cells allowed to differenti-
ate will spontaneously form neurons [18, 19],
cardiomyocytes [20, 21], muscle cells [22],
hematopoeitic cells [23] pancreatic precursor cells
[24, 25] and many other cell types [26-29]. Although
these procedures provide a starting point for pro-
ducing specific cells for possible applications, whether
in regenerative medicine, or as tools for drug discov-
ery or as disease models, little is understood about
the underlying mechanisms. Even if, limited success
has been achieved by manipulating culture conditions
to drive differentiation of human ES cells along par-
ticular lineages, there is little evidence to support the
view that such conditions specifically direct differen-
tiation rather than select for propagation or survival
of cells generated by spontaneous processes. A num-
ber of chemical agents and growth factors such as
retinoic acid or Bone morphogenetic proteins (BMP)
are well known to have physiological roles in embry-
onic development and have also been used to pro-
mote differentiation of ES cells in culture [30]. How-
ever, even in these cases, there is a tendency for dif-
ferentiation to follow broad lineages such as ecto-
dermal or mesodermal; the cell types generated also
tend to be heterogeneous [31].
Human embryonic stem cell (hESC)-based cell re-
placement therapies represents an attractive target
for type 1 diabetes [32]. Recently, it has been re-
ported that ES cells from mouse [33-40], monkey
[41] and human [42-44] were able to differentiate
into insulin positive cells. However, to date, studies
that reported the generation of insulin-positive cells
from ES cells, through cellular genetic manipulation
[40,45] or by utilization of specific culture conditions
[39,46] did not show a significant content of insulin
or a physiological regulation of insulin secretion. Ac-
tually, insulin secretion in differentiated ES cells never
exceeded 1.6% of the amount that a â-cell typically
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secretes. This is about the same production level
found in non- β insulin producing cells, such as fetal
liver cells or certain neuronal cells [47, 48].
Identification of a pancreatic progenitor cells would
be an important step to isolate large numbers of cells
that could be readily differentiated into islets or β-
cells.  Based on the expression of many neuronal cell
markers, a neuroectodermal origin of pancreatic en-
docrine cells has been hypothesized for many years.
It was suggested that nestin, the intermediate filament
protein which is expressed in neuronal precursors
might be a marker of islet progenitor cells [49]. Sev-
eral groups have used protocols designed to enrich
for neural precursors, characterized by expression
of nestin, in attempts to coax ES cells to adopt a
pancreatic islet fate [37, 50]. However, Lumelsky
and coworkers [37] observed that using a differen-
tiation protocol for neuronal progenitor cells, the dif-
ferentiation of nestin-positive ES cells into β-like cells,
had a limited effect. Only very few cells were insulin-
positive and the resulting cell aggregates did not ex-
press the Pdx-1 (pancreatic development homeobox
1, a homodomain protein absolutely required for pan-
creatic development in both human and mice) and
the majority of cells exhibited a neuronal phenotype.
There is some controversy about the use of nestin as
a progenitor marker and its significance in islet neo-
genesis. Some authors considered nestin as a neu-
roepithelial precursor marker (neural cell adhesion
molecule), which is also essential in multipotential
progenitor cells of pancreas, present both in rat and
in human pancreatic islets (called nestin-positive is-
let-derived progenitors) [50, 51]. Others have re-
ported that nestin only marks a population of mesen-
chymal or endothelial cell types, thereby excluding
role of nestin in islet cell development [52, 53]. Re-
cently, it has been demonstrated that the nestin posi-
tive cells in the pancreas of mice of different ages is
immunolocalized  with reference to insulin and gluca-
gon positive cells [54].
The proliferative capacity of ES cells is attractive but
their applications are limited due to risk of teratocar-
cinoma formation [35, 55]. The major concern with
ES cells is considerable ethical issues regarding the
use of human ES cells followed by their pluripotency
and plasticity, to create a mixture of many different
cells failing to produce the homologues population of
fully differentiated β-cells required for transplanta-
tion therapy [25]. Moreover, considering that ES cells
are by definition immortal, their poor survival when
differentiated was unexpected. Even though EC
would seem to constitute an ideal source for cell re-
placement therapies for many human diseases, re-
cent events have shown that some spectacular re-
sults in the field of ES cell research have to be reana-
lyzed very carefully [56].
The great advantage of ES cells over other stem cells
is that they can generate many potentially useful cell
types - but that is also their disadvantage. To use ES
cells effectively in regenerative medicine, or in other
applications, such as disease modeling or drug dis-
covery, applications that are often over looked in
popular discussion, is that it is essential to understand
how to control their differentiation. This is necessary
if one is to expand cultures of the undifferentiated
cells to a usable scale, free of potential pathogens. It
is also necessary if one is to produce specified cell
types, free of other unwanted cells, and if the genetic
fidelity of the cells is to be preserved, a factor that
was not immediately apparent when these cells were
first derived. These issues present substantial chal-
lenges [31]. Nevertheless, in diabetes research, hu-
man ES cells may help to decode some crucial steps
in vitro, since almost all the data available on pan-
creas development were obtained from animal mod-
els. To activate the differentiation programmes, ES
cells are forced to aggregate into embryonic bodies
(EBs) by culturing in suspension and in the absence
of leukemia inhibitory factor (LIF). These unique
properties make ES cells of great interest as a source
to obtain insulin producing cells for diabetes treat-
ment [57].
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Recent success in generating insulin-secreting islet-
like cells from human embryonic stem (ES) cells, in
combination with the success in deriving human ES
cell - like induced pluripotent stem (iPS) cells from
human fibroblasts by defined factors, have raised the
possibility that patient - specific insulin - secreting is-
let-like cells might be derived from somatic cells
through cell fate reprogramming using defined factors
[58]. Although the precise relationship of iPS and ES
cells remains to be explored in detail, the advent of
iPS cell technology circumvents the ethical, legal and
logistical problems associated with the need for hu-
man embryos to derive ES cell lines, and has started
a democratization process that should see a substan-
tial expansion in the study of pluripotent cell biology.
With all these results in mind, insulin producing, C-
peptide and glucagon positive islet-like clusters (ILCs)
from the iPS cells were derived from human skin cells
by retroviral expression of Oct4, SOX2, c-MYC,
and KLF4 under feeder-free conditions [59].  The
major hurdles that must be overcome to enable the
broad clinical translation of these advances include
teratoma formation by ES and iPS cells, and the need
for immunosuppressive drugs. Thus, the creation of
human - animal hybrid embryos by iPS - proposed
as a way to generate embryonic stem cells without
relying on scarce human eggs - has met with legisla-
tive hurdles and public outcry. But a very recent re-
port [60] suggests that the approach has another, more
fundamental problem: it may simply not work - as
these hybrid embryos fail to grow beyond 16 cells.
Hence, it is not yet sure whether iPS cells lives up to
all the great hopes given to them. The best strategy
would be ‘wait and watch’.
Adult Stem Cells:
Several adult tissues, including blood, epidermis, liver,
enterocytes and spermatogonia are replenished
throughout the life. This observation of the regenera-
tive potential of adult tissue led to the concept of adult
stem cells. Adult stem cells are rare cells with low
proliferation capacity, which according to present
hypotheses reside in stem cell niches and give rise to
a transient amplifying cell pool that differentiates,
thereby regenerating the respective tissues [61] ex-
cept germ layer and further classified as hematopoi-
etic stem cells [HSC] and mesenchymal stem cells
(MSC).
Although MSCs were originally isolated from bone
marrow [62], recent years have witnessed an explo-
sion in the number of adult stem cell populations iso-
lated and characterized. Every tissue or organ, from
adipose tissue [63, 64], placenta [65, 66], amniotic
fluid [67], umbilical cord blood [68, 69] etc. exhibits
stem cell population. Some studies have suggested
that there may be a greater degree of plasticity, per-
haps even pluripotency, associated with adult stem
cells than was previously believed. The multilineage
differentiation potential of MSCs derived from vari-
ety of different species has been extensively studied
in vitro since their first discovery in 1960 [70]. An
excitement ensued when, in 1998, Ferrari et al. [71]
showed transplantation of genetically marked bone
marrow into immunodeficient mice migrated into ar-
eas of induced muscle degeneration, undergo myo-
genic differentiation, and participated in the regen-
eration of the damaged fibers.  Subsequently, numer-
ous publications [72, 73,74] have described various
events, in which adult stem cells from one organ give
rise to cell type characteristics of different organ.
The capacity to differentiate into multiple mesenchy-
mal lineages including cartilage [75, 76], bone [77-
78], and adipose tissue [79, 80] is being used as a
functional criterion to define MSCs. This ability has
rendered MSC an ideal candidate cell source for clini-
cal tissue regeneration strategies, including the aug-
mentation and local repair and regeneration of spe-
cific lineage. Recent studies indicated the identifica-
tion of pluripotent cells that not only differentiate into
cells of mesoderm lineage, but also into endoderm
and neuroectoderm lineages, including neurons [81],
hepatocytes [82], and endothelia [83].
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Individual colonies derived from single MSC precur-
sors have also been reported to be heterogeneous in
terms of their multilineage differentiation potential. Only
one third of adherent bone marrow derived MSC
clones are pluripotent [84]. Furthermore,
nonimortalized cell clones examined by Muraglia et
al. [85] in 2000 demonstrated that 30% of the in vitro
derived MSC clones exhibited a tri-lineage (osteo-
genic/chondrogenic/adipogenic) differentiation poten-
tial, while the reminder displayed a bi-lineage (osteo-
genic/chondrogenic) or uni-lineage (osteogenic).
These observations are consistent with other in vitro
studies using conditional immortalized clones [86-88].
It has also been observed that only 58.8% of the single
colony derived clones had the ability to form bone
within Hydroxyapatite-tricalcium phosphate ceramic
scaffolds post implantation in immunodeficient mice
[89]. All these results indicate heterogeneous nature
of clonally derived MSCs with respect to their devel-
opmental potential.
At present, there is no specific marker or combina-
tion of markers have been identified that specifically
defined MSCs [90, 91]. Phenotypically, ex vivo ex-
panded MSCs express a number of non-specific
markers, including CD29, CD44, CD73, CD90,
CD105, CD166 [84, 92]. Despite this controversy
of what defines a mesenchymal stem cell, there is gen-
eral agreement that MSCs lack typical hematopoi-
etic antigens, namely CD14, CD34 and CD45 [84].
With specific regards to pancreatic lineages there has
been a report of differentiation/ transdifferentiation by
Ianus and colleagues [93] who studied in vivo dif-
ferentiation of adult bone marrow derived cells into
pancreatic endocrine cells. Their results suggested that
a population of cells within the bone marrow has the
capacity to transdifferentiate into cells that can popu-
late and perhaps function within, the endocrine pan-
creas. One study using streptozotocin (STZ) – in-
duced pancreas damage demonstrated that pancre-
atic cell proliferation was induced after bone marrow
transplantation [94]. The stem cells from bone mar-
row are capable of producing a whole spectrum of
cell types; highlighting the opportunity to manipulate
these cells for therapeutic use as they have been shown
to cross the lineage boundaries [95]. It has been
shown that the human bone marrow derived mesen-
chymal stem cells could be induced to differentiate
into functional insulin producing cells using Pdx-1,
delivered by recombinant adenovirus. More recent
reports suggest that bone marrow stem cells reversed
experimental diabetes in vivo by enhancing the re-
generation and survival of endogenous β-cells rather
than repopulating the islets with trans-differentiated
β-cells [96,97]. Several in vitro studies have dem-
onstrated that rodent bone marrow stem cells can
adopt an insulin-expressing phenotype [98], and driv-
ing the phenotype of human bone marrow stem cells
by the forced expression of β-cells transcription fac-
tors generated cells capable of glucose responsive
insulin secretion [99,100]. Banerjee and colleagues
have demonstrated reversal of experimental diabetes
in STZ diabetic mouse model by multiple injections
of unfractionated bone marrow leading to induction
of pancreatic regeneration, which is highly promising
[101], although the mechanism is not suggested. These
studies point towards futuristic therapeutic approach
of auto transplantation of bone marrow to cure dia-
betes.
Apart from bone marrow the mature liver has been
shown to serve as a potential source of tissue for gen-
erating functional endocrine pancreas. This may al-
low the diabetic patient to be the donor of his or her
own therapeutic tissue; thus alleviating both the needs
for allo-transplantation and the subsequent immune
suppression [102]. There have been sporadic reports
that progenitor/stem cells from other tissues can be
induced to differentiate into insulin expressing cells,
including cells localized to intestinal epithelium, der-
mis, spleen, salivary gland and blood monocytes, en-
dometrium / menstrual blood [103]. These studies
have not always proved to be reproducible, and have
been reviewed recently [104-106]. Thus, with the
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ability to differentiate into multiple lineages
(multipotent) and immunosuppressive effects, adult
stem cells became an attractive alternative to human
ES cells in regenerative medicine and cell-based
therapy against various human diseases including
type 1 diabetes [107].  In particular, adult stem cells
have many attractive features as a source of
functional transplantable cellular material when
compared to ES cells.
Fetal/extra-embryonic/post-natal stem cells:
Fetal stem cells, comprising of the final broad stem
cell class, have a comparatively recent history. They
can be isolated from two distinct sources, the fetus
proper and the supportive extra-embryonic structures.
Stem cells derived from the extra-embryonic sources
are particularly interesting due to their potential clini-
cal utility. Over the past decades fetal stem cells have
been isolated from multiple extra-embryonic tissues,
reminiscent of gradual broadening of stem cell sources
seen in the adult. Amniotic fluid, amnion, umbilical
cord blood, Wharton’s jelly and placenta have all
generated putative stem cells. These tissues, collec-
tively also known as the afterbirth (after the delivery
of foetus, placenta begins a physiological separation
for spontaneous expulsion afterwards along with all
umbilical cord, amnion etc. therefore, called the af-
terbirth) are routinely discarded at parturition as a
biological waste. However, this situation may change
in the near future, as a growing number of reports
demonstrated greater potential of  these tissues as
‘store house’ of stem cells which makes it a valuable
alternative stem cell source with fewer concerns in
terms of ethical controversy and moral issues [108]
of the resident stem cell populations.
The first isolated fetal stem cells were hematopoietic,
derived from human umbilical cord blood. The iso-
lated cells were capable of long-term self-renewal and
differentiation to multiple hematopoietic lineages [109,
110]. Clinically, cord blood stem cells were success-
fully employed in a bone marrow transplant in 1988
[111]. Stem cells from extra-embryonic tissue ex-
pressed a number of mesenchymal cell surface mark-
ers, including CD90 and CD105. Subsequent work
demonstrated the expression of Oct4 within a subset
of most of the extra-embryonic stem cells. This is
important, as Oct4 expression is associated with pluri-
potent cells such as embryonic germ cells and ES cells
[112-114]. This observation keeps extra- embryonic
stem cells poised to join embryonic and adult stem
cells. Following in vitro expansion, the isolated cells
were capable of differentiating in vitro into
chondrocytes, adipocytes and osteocytes. In addi-
tion to tri-lineage differentiation, stem cells derived
from umbilical cord [115,116], cord blood [117-119],
placenta [66,120], amniotic membrane [121,122]
have shown potential for differentiation into insulin
producing β-cells and have been considered as sur-
rogate β-cells source for islet transplantation. Most
importantly, an emerging body of data indicates that
MSCs possess immunomodulatory properties [123-
126] & may play specific roles as immunomodulators
in maintenance of peripheral tolerance, transplanta-
tion tolerance, autoimmunity, tumor evasion, as well
as fetal-maternal tolerance. These observations have
further raised clinical interest in adult and its counter-
part fetal MSCs.
Recent advance in adult/fetal stem cell technologies
and basic biology has accelerated therapeutic oppor-
tunities aimed at eventual clinical applications. First,
the extracorporeal nature of these stem cell sources
facilitates isolation, eliminating patient risk that attends
other adult stem cell isolation. Most significantly, the
comparatively large volume of extra-embryonic tis-
sues and ease of physical manipulation theoretically
increases the number of stem cells that can be iso-
lated. Second, ethical questions surrounding the use
of human embryonic stem cells are essentially absent
from the discussion of adult stem cells. Third, because
they can be isolated from the prospective patient, they
would be genetically matched, thus eliminating the need
for immunosuppressive therapies. Fourth, the puta-
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tive ability of extra embryonic stem cells to differen-
tiate into cells from multitude of lineage suggests their
use in treating a variety of diseases. Stem cells from
extra-embryonic tissues represent an emerging area
of research that bears tremendous potential with broad
application to many different areas including normal
and pathological development, assisted reproductive
technology procedures and regenerative medicine
[127].
The extra-embryonic/adult stem cells have opened
up the possibility of ‘fixing’ a particular genotype (ei-
ther normal or diseased) in pluripotent stem cells. Iso-
lation from tissues normally discarded at birth facili-
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tates easy harvest and overcomes ethical concerns.
The cells isolated from these tissues grow well in cul-
ture, appear capable of differentiation to multiple cell
types and may be less likely to be rejected following
transplantation. All these studies have prompted re-
searchers to examine the stem cell potential of the
biological waste tissues of human origin such as um-
bilical cord, placenta, amnion and endometrium and
to test their ability to differentiate into glucose respon-
sive insulin producing islet like clusters for possible
cell replacement therapy in diabetes as well as to cre-
ate an islet model for in vitro studies.
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